EZH2 and neoplasm: Previous work from our group indicates that PRC2 components (EZH2, EED, and SUZ12) are overexpressed in ATC, and targeting of EZH2 in BRAF‐mutated ATC cell lines with the FDA‐approved drug EPZ6438 (Tazemetostat) or with CRISPR/Cas9 improved gene expression of TDGs and inhibited cell migration, invasion, and in vivo tumor growth [15].